|Bid||7,300.00 x 0|
|Ask||7,410.00 x 0|
|Day's range||7,306.00 - 7,404.00|
|52-week range||5,312.00 - 7,479.00|
|Beta (3Y monthly)||1.05|
|PE ratio (TTM)||42.72|
|Forward dividend & yield||2.19 (2.99%)|
|1y target est||N/A|
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
CAC40 has best day since Aug. 8 * Fresh Renault, Fiat tie-up hopes boost shares Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: email@example.com CLOSING SNAPSHOT: BONHOMIE SWEEPS EUROPE (1613 GMT) Bonhomie has swept across European markets today, pushing the major bourses to multi-week highs at the close ahead of a critical speech from the Fed chief on Friday and amid improving sentiment around Italy. Paris' CAC 40 had its best day since Aug. 8, up 1.7%, "Markets are still in a mood to rally it seems, perhaps in hope that Jerome Powell will deliver a more accommodative outlook when he speaks on Friday," says Chris Beauchamp, chief market analyst at IG.
CAC40 set for best day since Aug. 8 * Fresh Renault, Fiat tie-up hopes boost shares Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: firstname.lastname@example.org DIVERGING FORTUNES IN EUROPE AND U.S. (1142 GMT) The divergence in fortunes between euro-zone stocks and their U.S. peers on the other side of the pond has widened markedly over the past week, the latest sign that investors are getting increasingly jittery about the bloc's economic outlook. There's a growing list of reasons to steer clear of the region: Italy's deepening political crisis, Germany's economic slowdown, Europe Inc's corporate recession and Brexit.
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs.
London's FTSE 100 rose on Wednesday as oil majors tracked gains in crude prices and exporters benefitted from a weaker pound, while markets waited for minutes of the U.S. Federal Reserve's July meeting for signs of further policy easing. NMC Health, a United Arab Emirates-based healthcare provider, climbed more than 4% to be among top FTSE 100 gainers ahead of Thursday's scheduled trading update.
Investors are getting jittery before Federal Reserve Chair Jerome Powell's speech on Friday. The Treasury yield curve has reversed its inversion for now, as talk of more stimulus efforts in China and Germany have soothed recession fears and markets seem to want to move higher – U.S. futures are up 0.3% and European shares are higher after a lacklustre session in Asia. The news on the Sino-U.S. trade front isn’t great either – U.S. President Donald Trump’s latest comment being that it was necessary to "take on" China even if it harmed the U.S. economy in the short term.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Thyagaraju Adinarayan. Reach him on Messenger to share your thoughts on market moves: email@example.com FUTURES POINT TO SMALL GAINS ON EERILY QUIET DAY (0658 GMT) European stock futures point to a slightly higher open today in a small relief as endless trade war worries, fresh political turmoil in Italy, Brexit and slowing economic growth have kept investors away from making risky bets. In the trade war, U.S. President Trump again showed no signs of backing down in his tussle with China, declaring on Tuesday a confrontation was necessary even if it caused short-term harm to the U.S. economy.
The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. London-listed AstraZeneca said that though the trial involved a wide range of patients, the primary group being tested had high levels of mutations in their DNA.
BEIJING/SHANGHAI, Aug 20 (Reuters) - China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance schemes, part of a push to lower patients' out-of-pocket costs in one of the world's largest drug markets, state media reported. AstraZeneca's Kombiglyze and Merck & Co's Janumet diabetes treatments are among the drugs that will now be covered by national insurance, according to the updated list published by China's National Healthcare Security Administration. As it published the updated list of 2,643 drugs on its website on Tuesday, the healthcare administration said the adjustment was crucial to improving the efficient use of the country's medical insurance funds.
I think these two FTSE 100 (INDEXFTSE:UKX) income shares could deliver significantly higher returns than a Cash ISA.
London's main index ended firmly in the red on Tuesday after new U.S.-China trade jitters and political instability in Italy took down heavyweight firms across sectors, while exporter stocks dipped as the pound gained after German Chancellor Angela Merkel's comments on the Brexit process. The FTSE 100 gave up earlier gains and shed 0.9%, though investors still hoped for fresh stimulus from central banks and governments to beat back the risk of recession. The FTSE 250 lost 0.5%.
AstraZeneca made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly. The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use.
The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use. Farxiga, already one of AstraZeneca's top 10 drugs by sales, met the main goal of the so-called DAPA-HF trial, which tested the medicine in addition to the standard treatment in patients whose heart cannot pump enough blood.
Don't shrink in the face of diving investor confidence. Grab your debit card and get a slice of these undervalued FTSE 100 (INDEXFTSE: UKX) income heroes, says Royston Wild.
AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer. Astra said on Wednesday its Lynparza drug, which blocks a cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body. The patient group that was examined in the so-called Paola-1 trial had been successfully given chemotherapy and Roche's Avastin as initial treatment following a diagnosis of advanced ovarian cancer.
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
Looking for great FTSE 100 (INDEXFTSE: UKX) income heroes to buy for 2020? These two could be just the ticket, argues Royston Wild.
Italy's government is on the brink of collapse after the leader of the ruling League party, Matteo Salvini, called the governing coalition with 5-Star unworkable and said the only way forward was to hold fresh elections. 5-Star has more parliamentary seats than the League, but Salvini's party now has twice as much voter support, polls show, making it well placed to benefit from a snap election.